 |
Monoamine Oxidase Inhibitors
Research News and Information
Definition of 'Monoamine Oxidase Inhibitors'A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) Common names: Monoamine Oxidase Inhibitors; Inhibitors, Monoamine Oxidase; MAO Inhibitors; Inhibitors, MAO; Monoamine Oxidase Inhibitor; Inhibitor, Monoamine Oxidase; Reversible Inhibitors of Monoamine Oxidase; Reversible Inhibitor of Monoamine Oxidase; RIMA (Reversible Inhibitor of Monoamine Oxidase A) |
Monday, November 23, 2009
24 Sep 2009 
The aim of the present study was examining the effects of some 1,3,5-trisubstituted-2-pyrazoline derivatives on depression, anxiety and spontaneous locomotor activity parameters of mice. None of the compounds was effective at 50 mg/kg dose whereas ... Read more...
A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
22 Sep 2009 BACKGROUND: A therapy that slows disease progression is the major unmet need in Parkinson's disease. METHODS: In this double-blind trial, we examined the possibility that rasagiline has disease-modifying effects in Parkinson's disease. A total of ... Read more...
Linezolid: a review of safety and tolerability.
30 Aug 2009 Linezolid has demonstrated activity against antibiotic-susceptible and antibiotic-resistant aerobic Gram-positive cocci. The availability of intravenous and oral formulations, with near 100% bioavailability of the latter, is hoped to facilitate the ... Read more...
Latest indexed articles for 'Monoamine Oxidase Inhibitors'
These are the very latest articles for this heading:
- Effects of some 1,3,5-trisubstitued-2-pyrazoline derivatives on depression and anxiety parameters of mice. 24 Sep 2009
- A double-blind, delayed-start trial of rasagiline in Parkinson's disease. 22 Sep 2009
- Linezolid: a review of safety and tolerability. 30 Aug 2009
- TCP-FA4: a derivative of tranylcypromine showing improved blood-brain permeability. 9 Aug 2009
- Serotonin produces monoamine oxidase-dependent oxidative stress in human heart valves. 5 Aug 2009
- Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. 30 Jul 2009
- Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression. 30 Jul 2009
- A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion. 30 Jul 2009
- Medical treatment of Parkinson disease. 30 Jul 2009
- Glucocorticoid status affects antidepressant regulation of locus coeruleus tyrosine hydroxylase and dorsal raphé tryptophan hydroxylase gene expression. Jul 2009
- First-line pharmacotherapies for depression - what is the best choice? 29 Jun 2009
- Downregulation of oligodendrocyte transcripts is associated with impaired prefrontal cortex function in rats. 29 Jun 2009
- Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics. 29 Jun 2009
- Calcium alters monoamine oxidase-A parameters in human cerebellar and rat glial C6 cell extracts: possible influence by distinct signalling pathways. 15 Jun 2009
- Antidepressant action of tianeptine is connected with acceleration of serotonin turnover in the synapse: a hypothesis. 30 May 2009
- MAOA gene polymorphisms and response to mirtazapine in major depression. 30 May 2009
- Chalcones: a valid scaffold for monoamine oxidases inhibitors. 12 May 2009
- Development of spin-labeled pargyline analogues as specific inhibitors of human monoamine oxidases A and B. 10 May 2009
- Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon.
6 May 2009 - [Combining antidepressants: a useful strategy for therapy resistant depression?] 2 May 2009
See a longer list of these articles.
Technical information about 'Monoamine Oxidase Inhibitors'
Definition: A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414)
Registry Number: 0
Descriptor UI: D008996
Alternative terms: Monoamine Oxidase Inhibitors; Inhibitors, Monoamine Oxidase; MAO Inhibitors; Inhibitors, MAO; Monoamine Oxidase Inhibitor; Inhibitor, Monoamine Oxidase; Reversible Inhibitors of Monoamine Oxidase; Reversible Inhibitor of Monoamine Oxidase; RIMA (Reversible Inhibitor of Monoamine Oxidase A);
Related Mesh Headings: Antidepressive Agents;
Allowable Qualifiers: administration & dosage; adverse effects; analysis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;
Tree Number: D27.505.519.389.616;
Technical Notes: DF: MAO INHIB